ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer’s Hallmarks in Preclinical Disease Model
M1 muscarinic agonists and a multipotent activator of sigma1/M1 muscarinic receptors: Future therapeutics of Alzheimer’s disease (AD)
Anavex Reports That New Data Confirms Calcium Target Over-Expression May Be Involved in Causing Alzheimer’s Disease
Anavex Provides Business Update Including Clinical Trial Plans for ANAVEX PLUS in Alzheimer’s Disease
